Aging comes with chronic inflammation and stem cell exhaustion, and the mTORC1 signaling pathway is considered one of the main conductors of these processes. Neighboring papers in the archive explore aging as a loss of regulatory control and the methylation landscapes of individual cells, but the question remains open: how does long-term pharmacological intervention in this pathway affect the immune system as a whole? This work places rapamycin in the context not just of life extension, but of reshaping the immune response during aging.
C57BL/6J mice aged 6–8 or 17–19 months were fed chow with microencapsulated rapamycin (14 ppm of the active compound) for five months. The control group received the same chow with a Eudragit coating but no drug. Then the composition of immune cells in blood, bone marrow, spleen, lymph nodes, and peritoneal fluid was assessed by flow cytometry. A separate cohort was stimulated with an intraperitoneal injection of lipopolysaccharide (LPS), and four hours later serum cytokines and inflammatory gene expression in microglia were measured.
Rapamycin did not change the proportion of monocytes and neutrophils in any of the compartments studied, nor did it affect B cell subpopulations. Among T cells, only a slight shift toward memory cells was noted, consistent with previous data. The key effect showed up in gamma-delta T cells: rapamycin prevented the age-related accumulation of CD27-negative cells producing IL-17, bringing their levels back to those of young animals. After LPS stimulation, mice on rapamycin had significantly lower serum levels of IL-12p40, IL-17A, and IL-27, and microglial expression of Tnf-α, Il6, and Tlr2 was reduced. At the same time, basal cytokine levels and markers of neuroinflammation remained unchanged.
Unlike neighboring papers that describe the cellular and molecular landscapes of aging without intervention, this study is the first to show that long-term low-dose mTORC1 inhibition in aged mice acts selectively: it leaves the overall immune cell composition alone but dampens a specific IL-17 inflammatory axis and microglial reactivity. This shifts the focus from the question 'does rapamycin suppress immunity?' to 'which signals does it retune?' The work fits the search for safe geroprotectors, but adds the missing link about tissue-specific effects.
The topic could move toward uncovering the mechanism linking peripheral gamma-delta T cells to microglia: perhaps IL-17 acts directly on microglial receptors, or the effect is mediated by the gut microbiome through the gut–brain axis. It would also be promising to test whether such a diet improves resistance to infections and cognitive function in neuroinflammation models.
The results will influence preclinical trials of rapamycin and its analogs as geroprotectors, as well as our understanding of the role of gamma-delta T cells in age-related neuroinflammatory pathology.
To test whether the observed effects carry over to models of age-related diseases, and to determine which peripheral signals specifically alter microglial reactivity.
The work addresses an unresolved problem in immunosenescence: how to separate beneficial suppression of chronic inflammation from harmful immunosuppression. It shows that fine modulation of mTORC1 may be the key to safe intervention.
Rapamycin was discovered in a soil sample from Easter Island and named after the island's local name, Rapa Nui. It was first used as an antifungal, and its immunosuppressive properties were discovered later.
The idea of a drug that slows aging without breaking the body echoes the motif of a 'soft' geroprotector from Bruce Sterling's novel Schismatrix, where life extension is achieved through fine-tuning biology rather than blunt intervention.
Not published on arXiv. Here are its page, the PDF and the formalization: you can check it yourself, not only read our account.